ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oxycodone

Also written as “Reformulated OXY (oxycodone HCl)”, “Oxycodone/Naloxone” and “oxycodone hydrochloride”.

Its studies are mostly in Pain · Neoplasms · Osteoarthritis · Cancer Pain · Chronic Pain, led by 13 companies.

Drug pageOxycodone: every studyMany companies study it; this page follows only the 64 they lead. All 209 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 8, 201164 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mundipharma200 open or runningphase 4since Mar 8, 2011Jul 27, 2007none ahead
Knoa Pharmaits history only120 open or runningphase 3since Apr 6, 2006Apr 6, 2006none ahead
Pain Therapeuticsits history only120 open or runningphase 3since Mar 13, 2012Aug 12, 2008none ahead
Pfizerits history only60 open or runningphase 4since Jun 8, 2007Jun 8, 2007none ahead
Egaletits history only30 open or runningphase 3since Nov 10, 2015Dec 2, 2008none ahead
Keenova Therapeuticsits history only30 open or runningphase 1since Feb 26, 2009Feb 26, 2009none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
biodelivery-sciences-internationalits history only10 open or runningphase 1since Jun 21, 2019Jun 21, 2019none ahead
elite-laboratories-incits history only10 open or runningphase 3since Feb 17, 2015Feb 17, 2015none ahead
gl-pharm-tech-corporationits history only10 open or runningphase 1since Mar 19, 2012Mar 19, 2012none ahead

Also a collaborator on its studies: PRA Health Sciences and Grünenthal.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mundipharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jul 27, 2007.

  1. Feb 23, 2011Phase 3 study in Other Acute Postoperative PainNCT01304134 · 240 enrolled · China
  2. Mar 8, 2011Phase 4 study in NeoplasmsNCT01313780 · 128 enrolled · Korea, Republic of
  3. Aug 18, 2011Phase 3 study in PainNCT01438567 · 270 enrolled · United Kingdom
  4. Sep 21, 2011Phase 3 study in Parkinson DiseaseNCT01439100 · 172 enrolled · Czech Republic, Germany, Hungary and more
  5. Nov 17, 20112 phase 1 studies in PainNCT01643772, NCT01482936
  6. Apr 25, 20122 phase 3 studiesNCT01675635, NCT01675622
  7. Oct 8, 20122 phase 4 studiesNCT01719757, NCT01811238
  8. Mar 12, 2013Phase 4 study in Chronic PainNCT01811186 · 261 enrolled · Korea, Republic of
  9. Jun 19, 2013Phase 3 study in NeoplasmsNCT01885182 · 232 enrolled · China
  10. Aug 5, 2013Phase 3 study in Non Cancer PainNCT01918098 · 230 enrolled · China
  11. Oct 13, 2014Phase 3 study in Bronchiolitis Obliterans SyndromeNCT02321397 · 155 enrolled · Germany
  12. Jan 18, 2016Phase 4 study in Cancer PainNCT02660229 · 66 enrolled · Korea, Republic of
  13. May 22, 2017Phase 4 study in NeoplasmsNCT03176121 · 73 enrolled · Taiwan
  14. Jun 1, 2017Phase 4 study in NeoplasmsNCT03176199 · 30 enrolled · Taiwan

TargetBeta

OPRM1 →read by rule
“Mu opioid receptor agonist; Mu opioid receptor agonist; Mu opioid receptor agonist”ChEMBL 37, by rule

Other programs on OPRM1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
MethadoneruleMerckphase 416
cebranopadolruleTris Pharmaphase 318
axelopranruleglycyx-therapeuticsphase 28
AlfentanilruleSichuan Kelun Pharmaceuticalphase 11

Studies

All 20 Mundipharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03176199Neoplasms · Taiwan4CompletedDec 31, 201830
NCT03176121Neoplasms · Taiwan4CompletedDec 31, 201873
NCT02660229Cancer Pain · Korea, Republic of4CompletedJul 201666
NCT02321397Bronchiolitis Obliterans Syndrome · Germany3CompletedMar 2016155
NCT01918098Non Cancer Pain · China3CompletedMar 30, 2017230
NCT01885182Neoplasms · China3CompletedAug 30, 2015232
NCT01811186Chronic Pain · Korea, Republic of4CompletedJan 2014261
NCT01811238Spinal Disorders4CompletedApr 2013240
NCT01719757Neoplasms · Korea, Republic of4CompletedOct 2013359
NCT01675635Pain, Postoperative3CompletedJun 2012240
NCT01675622Neoplasms3CompletedJun 2012242
NCT01643772Pain · China1CompletedJul 201261
NCT01482936Pain · China1CompletedApr 201144
NCT01439100Parkinson Disease · Czech Republic, Germany, Hungary and more3CompletedAug 2013172
NCT01438567Pain · United Kingdom3CompletedFeb 2014270
NCT01313780Neoplasms · Korea, Republic of4CompletedOct 2013128
NCT01304134Other Acute Postoperative Pain · China3CompletedAug 2010240
NCT01167699Pain · Belgium3CompletedApr 2011174
NCT00626600Cancer Pain · United Kingdom3TerminatedMay 200933
NCT00513656Neoplasms · United Kingdom2CompletedMar 2010230

How it is read

Names in the registry

  • “Oxycodone”, 43 entries
  • “Reformulated OXY (oxycodone HCl)”, 6 entries
  • “Oxycodone/Naloxone”, 5 entries
  • “oxycodone hydrochloride”, 4 entries
  • “Oxycodone hydrochloride”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.